Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
Company criticizes lack of details on how CMS plans to implement final ESA coverage policy for non-renal disease patients and suggests stakeholders are looking at ways to get alter the policy.
You may also be interested in...
Amgen Restructures Amid Anemic Aranesp Sales
Biotech will eliminate up to 2,600 jobs, prioritize R&D spend to achieve $1 billion to $1.3 billion in pre-tax savings.
EPO Use OK In All But Eight Cancer Conditions, Medicare NCD Says
Final National Coverage Determination issued July 30 drops number of restricted uses of erythropoiesis-stimulating agents from the 13 listed in the draft NCD.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.